Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Spherix Global Insights
Marketing
Novo's oral semaglutide is PCPs' most-anticipated obesity med
As both Novo Nordisk and Eli Lilly race to develop oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers.
Andrea Park
Dec 15, 2025 3:46pm
Novo's Wegovy in line for a 'swift' adoption in MASH: Spherix
Aug 29, 2025 11:40am
AbbVie’s Skyrizi passes Lilly’s Omvoh to take lead in colitis
Oct 7, 2024 10:53am
Docs discuss ongoing Humira use, name preferred biosimilars
Sep 24, 2024 7:20am
Off-label drugs fall out of favor in lupus
Jun 16, 2023 10:16am
Eisai's Leqembi gaining ground with US neurologists
Apr 11, 2023 10:00am
